JP2017523789A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523789A5
JP2017523789A5 JP2017506395A JP2017506395A JP2017523789A5 JP 2017523789 A5 JP2017523789 A5 JP 2017523789A5 JP 2017506395 A JP2017506395 A JP 2017506395A JP 2017506395 A JP2017506395 A JP 2017506395A JP 2017523789 A5 JP2017523789 A5 JP 2017523789A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
polypeptide
subject
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523789A (ja
JP6723982B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043792 external-priority patent/WO2016022671A1/en
Publication of JP2017523789A publication Critical patent/JP2017523789A/ja
Publication of JP2017523789A5 publication Critical patent/JP2017523789A5/ja
Application granted granted Critical
Publication of JP6723982B2 publication Critical patent/JP6723982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506395A 2014-08-06 2015-08-05 インターロイキン−2/インターロイキン−2受容体アルファ融合タンパク質および使用方法 Active JP6723982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
US62/033,726 2014-08-06
PCT/US2015/043792 WO2016022671A1 (en) 2014-08-06 2015-08-05 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020108721A Division JP7272663B2 (ja) 2014-08-06 2020-06-24 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法

Publications (3)

Publication Number Publication Date
JP2017523789A JP2017523789A (ja) 2017-08-24
JP2017523789A5 true JP2017523789A5 (enExample) 2018-09-13
JP6723982B2 JP6723982B2 (ja) 2020-07-15

Family

ID=53836871

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017506395A Active JP6723982B2 (ja) 2014-08-06 2015-08-05 インターロイキン−2/インターロイキン−2受容体アルファ融合タンパク質および使用方法
JP2020108721A Active JP7272663B2 (ja) 2014-08-06 2020-06-24 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法
JP2023069282A Pending JP2023099045A (ja) 2014-08-06 2023-04-20 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020108721A Active JP7272663B2 (ja) 2014-08-06 2020-06-24 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法
JP2023069282A Pending JP2023099045A (ja) 2014-08-06 2023-04-20 インターロイキン-2/インターロイキン-2受容体アルファ融合タンパク質および使用方法

Country Status (32)

Country Link
US (3) US12084483B2 (enExample)
EP (2) EP4438621A3 (enExample)
JP (3) JP6723982B2 (enExample)
KR (1) KR102653758B1 (enExample)
CN (2) CN107074967B (enExample)
AU (3) AU2015301071C1 (enExample)
BR (1) BR112017001940A2 (enExample)
CA (1) CA2957273C (enExample)
CL (1) CL2017000284A1 (enExample)
CO (1) CO2017002166A2 (enExample)
DK (1) DK3177307T3 (enExample)
EA (2) EA202091342A3 (enExample)
ES (1) ES2986097T3 (enExample)
FI (1) FI3177307T3 (enExample)
HR (1) HRP20241258T1 (enExample)
HU (1) HUE068478T2 (enExample)
IL (2) IL250007B (enExample)
LT (1) LT3177307T (enExample)
MA (2) MA40094B1 (enExample)
MX (1) MX388977B (enExample)
MY (1) MY180831A (enExample)
PE (1) PE20170503A1 (enExample)
PH (1) PH12017500042A1 (enExample)
PT (1) PT3177307T (enExample)
RS (1) RS65930B1 (enExample)
SA (1) SA517380842B1 (enExample)
SG (2) SG10201913695PA (enExample)
SI (1) SI3177307T1 (enExample)
SM (1) SMT202400414T1 (enExample)
TN (1) TN2017000020A1 (enExample)
WO (1) WO2016022671A1 (enExample)
ZA (1) ZA201700245B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
JP7178906B2 (ja) * 2016-05-19 2022-11-28 ザ ジェネラル ホスピタル コーポレイション ナチュラルキラー細胞および制御性T細胞の活性を強化するためのプラットフォームである、その受容体IL-2Rβに繋ぎ止められたインターロイキン-2
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3746103A4 (en) 2017-12-06 2022-03-30 The Board of Trustees of the Leland Stanford Junior University PROTEINS ENGINEERED TO INCREASE A CELL'S SENSITIVITY TO IL-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3768700A1 (en) 2018-03-23 2021-01-27 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
PE20210313A1 (es) * 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
WO2020187848A1 (en) 2019-03-18 2020-09-24 Biontech Cell & Gene Therapies Gmbh Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
US20220227837A1 (en) * 2019-05-24 2022-07-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
US20210038684A1 (en) * 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
EP3997115A4 (en) * 2019-07-12 2023-11-22 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
BR112022001320A2 (pt) * 2019-07-25 2022-04-12 Univ Chicago Composições e métodos compreendendo agentes terapêuticos ativados por protease
US20220378933A1 (en) * 2019-09-19 2022-12-01 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
BR112022007158A2 (pt) * 2019-10-18 2022-07-05 Alkermes Pharma Ireland Ltd Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
EP4143220A4 (en) 2020-04-30 2024-05-29 Immune Targeting Inc. COMPOSITION OF ACTIVATABLE IL2 AND METHODS OF USE
CN116194480A (zh) * 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
WO2023154894A2 (en) * 2022-02-11 2023-08-17 Alkermes Pharma Ireland Limited Compositions and methods for cancer immunotherapy
US20250154216A1 (en) * 2022-02-16 2025-05-15 University Of Miami Il-2 and tl1a fusion proteins and methods of use thereof
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
AU2024224039A1 (en) * 2023-02-22 2025-06-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-il2ra antibodies and uses thereof
WO2025207491A1 (en) * 2024-03-25 2025-10-02 Mural Oncology, Inc. Compositions and methods for cancer immunotherapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
EP0796280B1 (en) * 1994-12-28 2003-03-26 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
KR20040040475A (ko) 2001-09-28 2004-05-12 가부시키가이샤 디나벡크 겐큐쇼 에피토프 결합 β2m을 코드하는 포유동물 세포감염성 바이러스 벡터 및 그의 이용
US20060234205A1 (en) 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
CN101255197B (zh) * 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP2553101A4 (en) * 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
WO2012088383A2 (en) 2010-12-23 2012-06-28 Genentech, Inc. PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Similar Documents

Publication Publication Date Title
JP2017523789A5 (enExample)
FI3177307T3 (fi) Interleukiini-2/interleukiini-2-reseptori alfa-fuusioproteiinit ja niiden käyttömenetelmät
US12285462B2 (en) pH-triggered membrane peptide-mediated epitope tethering at cell surfaces
DK2633865T3 (en) USE OF INTERLEUKIN-22 IN THE TREATMENT OF VIRAL HEPATITIS
JP2014525901A5 (enExample)
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
HRP20161450T1 (hr) Stabilizirana varijanta aktivinskog receptora iib
RU2014135053A (ru) Иммуногены для вакцинации против вич
CN109689086A (zh) 具有延长的血清半衰期的融合蛋白
JP2015524413A5 (enExample)
CN107698684A (zh) 包含突变的免疫球蛋白Fc部分的GLP‑1融合蛋白
JP2014510519A5 (enExample)
JP2015511599A5 (enExample)
NZ760008A (en) Uti fusion proteins
CN121319219A (zh) Il2突变蛋白
JP2016019527A (ja) B細胞活性化因子の拮抗物質、その調製方法及び利用法
RU2010141916A (ru) Растворимый мутант рецептора фактора некроза опухоли
JP2020518613A5 (enExample)
KR20240164594A (ko) 설계된 사이토카인 조성물 및 사용 방법
AU2024288570A1 (en) Designed interleukin-2 cytokine compositions and methods for use
JP6431476B2 (ja) オステオプロテゲリン由来の組成物およびその使用
WO2023071390A1 (zh) 一种重组白介素-15变体
CN116375880A (zh) 融合蛋白及其制备方法和应用
US20100055135A1 (en) Enhancin of hepatitis b virus vaccine and its gene
CN117384298A (zh) 一种快速规模化生产病毒样颗粒疫苗或药物的方法